FDMT - 4D Molecular Therapeutics Inc

NYSE * Health Care * Biotechnology

$8.46

$-0.87 (-9.32%)

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California.

FDMT Key Statistics

Market Cap

$533.07M

0

P/B Ratio

1.29

EPS

$-3.75

Revenue Growth

+29.0%

Employees

227

How FDMT Compares to Peers

FDMT has the fastest revenue growth among competitors
FDMT is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

#1

of 6

Size Rank

#6

of 6

CompanyP/EGrowthCompare
FDMTN/A29%-
AMGN27.10%vs AMGN
GILD22.10%vs GILD
VRTX31.70%vs VRTX
REGN19.00%vs REGN
BIIB21.4-0%vs BIIB

4D Molecular Therapeutics Inc Company Information

Headquarters
California; U.S.A
Website
www.4dmoleculartherapeutics.com
Sector
Health Care
Industry
Biotechnology
Data Updated:
Ready to invest in FDMT?

Commission-free trading available. Affiliate links.

FDMT Lician Score

5% confidence
6.0/10
Good

FDMT has a Lician Score of 6/10 (Good). Strengths: Growth.

value

5.0

growth

7.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates FDMTacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

FDMT Financial Snowflake

5-axis analysis across key investment dimensions

5.4/10

Neutral

35810Value5.0Growth7.0Quality5.0Momentum5.0Safety5.05.4/10
5.0

Value

7.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for FDMT